Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
INCB028060 · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| INCB028060 | EXPERIMENTAL | Subjects will be enrolled and treated in cohorts of three and each observed a minimum of 28 days before the next group of patients may be enrolled and receive study drug. The initial cohort will be treated with 10 mg QD. The second cohort will be treated with 20 mg QD. The third cohort will be treated with 50 mg QD. Subsequent cohorts will be treated with two times the dose of the prior cohort to a limited toxicity level. |
| Name | Type | Description |
|---|---|---|
| INCB028060 | DRUG | 10 mg and 50 mg capsules will be provided and dosed per the dosing schedule. |
Inclusion Criteria: * Subjects with neoplastic disease refractory to currently available therapies or for which no effective treatment is available * Subjects with life expectancy of 12 weeks or longer. * Subjects with Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2. Excl...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
INCB028060 is an investigational small molecule being studied for the treatment of solid tumors, including advanced and metastatic cancer. It is currently in Phase 1 clinical development and has not been approved by the FDA.
INCB028060 is being developed by Incyte Corporation, a biopharmaceutical company traded on the NASDAQ under the ticker symbol INCY.
INCB028060 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA for any use.
INCB028060 has been studied in a Phase 1 dose-escalation trial, NCT01072266, titled "A Dose-escalation Study in Subjects With Advanced Malignancies." The trial enrolled 45 participants with solid tumors, advanced cancer, or metastatic cancer in the United States and has been completed.
Yes, INCB028060 is a small molecule therapeutic developed for oncology indications. It is being investigated as a potential treatment for solid tumors.